Victor Vazquez, MD
Hematology & Oncology · Aguadilla, PRNPI 1427266956
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.5%), consulting fees and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 45.1% of the total. That places this record below the midpoint for hematology & oncology clinicians in PR, where the typical reported total is $10,882.
Across 195 payments — averaging $45.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$4K
- Johnson & Johnson$1K
- AstraZeneca$702
- AbbVie$367
- Amgen$323
- Karyopharm Therapeutics Inc.$202
- plus $2K from 28 others
What the payments were for
- Consulting fees$3,33938%
- Food & beverage$5,08957%
- Education$4235%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 29 | $3,988 |
| Johnson & Johnson(2 entities) | 37 | $1,001 |
| AstraZeneca | 22 | $702 |
| AbbVie | 13 | $367 |
| Amgen | 6 | $323 |
| Karyopharm Therapeutics Inc. | 5 | $202 |
| Merck | 10 | $196 |
| Pfizer | 7 | $186 |
| PBG Puerto Rico LLC | 8 | $160 |
| Sobi, Inc | 6 | $154 |
| Immunogen, Inc. | 2 | $130 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Genentech, Inc. | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $123 |
| Novartis | 4 | $107 |
| Sanofi | 4 | $102 |
| Gilead(2 entities) | 4 | $100 |
| Tempus AI, Inc | 4 | $95 |
| Eli Lilly Export S.A. Puerto Rico Branch | 4 | $93 |
| Genentech USA, Inc. | 4 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Exelixis Inc. | 3 | $73 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Incyte Corporation | 2 | $39 |
| Seagen Inc. | 2 | $38 |
| GSK | 2 | $31 |
| Eisai Inc. | 1 | $30 |
| Caris MPI, Inc. | 1 | $28 |
| Bayer Puerto Rico Inc. | 1 | $25 |
| Adaptive Biotechnologies Corporation | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Bayer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,851 in reported general payments places this provider in the 45th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 66 | $982,835 |
| IbrancePalbociclib | 53 | $852,237 |
| ErleadaApalutamide | 53 | $698,523 |
| RevlimidLenalidomide | 31 | $601,727 |
| CabometyxCabozantinib S-Malate | 23 | $589,023 |
| PomalystPomalidomide | 18 | $417,454 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $394,352 |
| ImbruvicaIbrutinib | 24 | $391,004 |
| SprycelDasatinib | 31 | $355,515 |
| XtandiEnzalutamide | 23 | $328,906 |
| VenclextaVenetoclax | 30 | $313,868 |
| NubeqaDarolutamide | 21 | $287,883 |
| TagrissoOsimertinib Mesylate | 16 | $278,146 |
| JaypircaPirtobrutinib | 24 | $260,739 |
| JakafiRuxolitinib Phosphate | 14 | $243,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Bosulif, Retacrit | $186 | $1,143,73293 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $3,988 | $772,96949 claims |
| Johnson & JohnsonErleada | $1,001 | $698,52353 claims |
| Exelixis Inc.Cabometyx | $73 | $589,02323 claims |
| AstraZenecaTagrisso, Calquence | $702 | $460,71828 claims |
| GSKOjjaara | $31 | $394,35214 claims |
| NovartisMekinist, Promacta, Tafinlar | $107 | $380,62737 claims |
| Astellas Pharma US IncXtandi | $21 | $328,90623 claims |
| AbbVieVenclexta, Synthroid | $367 | $315,30652 claims |
| BayerNubeqa | $19 | $287,88321 claims |
| Incyte CorporationJakafi | $39 | $243,70814 claims |
| Genentech USA, Inc.Erivedge | $79 | $175,71313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Aguadilla
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Joel Lopez-FigueroaHumacao$163K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Carlos Mendez SerranoCaguas$91K
- Santa MerleMoca$84K
- Edgardo Santiago-GuzmanSan Juan$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.